Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence

被引：0
|
作者：
Chabre, Olivier [1 ]
Muller, Marie [2 ]
Cristante, Justine [1 ]
Cracowski, Jean-Luc [3 ]
Gay, Emmanuel [4 ]
机构：
[1] Univ Grenoble Alpes, CHU Grenoble Alpes, CEA,UGA, Unite Mixte Rech,Serv Endocrinol,INSERM,UMR 1036, F-38000 Grenoble, France
[2] CHU Grenoble Alpes, Serv Endocrinol, Grenoble, France
[3] Grenoble Alpes Univ, Pharmacovigilance Dept, INSERM, UMR 1300,Lab HP2, Grenoble, France
[4] Univ Grenoble Alpes, CHU Grenoble Alpes, Serv Neurochirurg, Grenoble, France
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2022年 / 10卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：384 / 385
页数：2
相关论文
共 50 条
  • [21] Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease
    Yuen, Kevin C. J.
    ENDOCRINE PRACTICE, 2021, 27 (09) : 956 - 965
  • [22] Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples
    Fleseriu, Maria
    Biller, Beverly M. K.
    PITUITARY, 2022, 25 (06) : 795 - 809
  • [23] Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
    Maria Fleseriu
    Beverly M. K. Biller
    Pituitary, 2022, 25 : 795 - 809
  • [24] Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension
    Gadelha, Monica
    Snyder, Peter J.
    Witek, Przemyslaw
    Bex, Marie
    Belaya, Zhanna
    Turcu, Adina F.
    Feelders, Richard A.
    Heaney, Anthony P.
    Paul, Michaela
    Pedroncelli, Alberto M.
    Auchus, Richard J.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [25] Efficacy of medical treatment in Cushing's disease: a systematic review
    Gadelha, Monica R.
    Neto, Leonardo Vieira
    CLINICAL ENDOCRINOLOGY, 2014, 80 (01) : 1 - 12
  • [26] Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia
    Dzialach, Lukasz
    Sobolewska, Joanna
    Respondek, Wioleta
    Wojciechowska-Luzniak, Agnieszka
    Witek, Przemyslaw
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2022, 21 (04): : 735 - 742
  • [27] Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension
    Fleseriu, Maria
    Newell-Price, John
    Pivonello, Rosario
    Shimatsu, Akira
    Auchus, Richard J.
    Scaroni, Carla
    Belaya, Zhanna
    Feelders, Richard A.
    Vila, Greisa
    Houde, Ghislaine
    Walia, Rama
    Izquierdo, Miguel
    Roughton, Michael
    Pedroncelli, Alberto M.
    Biller, Beverly M. K.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 187 (04) : 531 - 541
  • [28] Efficacy and tolerance of osilodrostat in patients with severe Cushing's syndrome due to non-pituitary cancers
    Haissaguerre, Magalie
    Puerto, Marie
    Nunes, Marie-Laure
    Tabarin, Antoine
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 183 (04) : L7 - L9
  • [29] Adrenal Cushing ' s Syndrome Treated With Preoperative Osilodrostat and Adrenalectomy
    Malik, Risha B.
    Ben-Shlomo, Anat
    AACE CLINICAL CASE REPORTS, 2022, 8 (06): : 267 - 270
  • [30] A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease
    Tanaka, Tomoaki
    Satoh, Fumitoshi
    Ujihara, Makoto
    Midorikawa, Sanae
    Kaneko, Tomomi
    Takeda, Tamami
    Suzuki, Akina
    Sato, Masahiko
    Shimatsu, Akira
    ENDOCRINE JOURNAL, 2020, 67 (08) : 841 - 852
12345